RxDoctor Payments Data

Donald Peavy, MD

Ophthalmology · Baton Rouge, LANPI 1033271317

Payments from drug & device makers

$3,867in general payments, 2019–2025

Across 113 payments — averaging $34.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Johnson & Johnson Surgical Vision, Inc.$595
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$414
  • Sun Pharmaceutical Industries Inc.$176
  • AbbVie$152
  • Nova Eye, Inc.$110
  • plus $259 from 10 others

What the payments were for

  • Travel & lodging$3549%
  • Food & beverage$3,40488%
  • Entertainment$1103%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,867 in reported general payments places this provider in the 65th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$158,244
Medicare patients
619
Services billed
1,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine27$26,311
LumiganBimatoprost62$23,856
IlevroNepafenac63$23,213
VyzultaLatanoprostene Bunod44$22,429
Alphagan PBrimonidine Tartrate53$19,315
Prednisolone Acetate441$16,338
CombiganBrimonidine Tartrate/Timolol38$15,216
RocklatanNetarsudil Mesylat/Latanoprost18$9,939
Travoprost71$9,139
SimbrinzaBrinzolamide/Brimonidine Tart33$6,997
Tobramycin-DexamethasoneTobramycin/Dexamethasone155$6,522
Latanoprost554$5,392
Ketorolac Tromethamine167$5,049
Brimonidine Tartrate58$4,210
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat235$3,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$152$84,698180 claims
Bausch & Lomb Americas Inc.Vyzulta$44$22,42944 claims
Aerie Pharmaceuticals, Inc.Rocklatan$21$9,93918 claims
AlconSimbrinza$2,161$6,99733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →